DELIVER Data and Phase-3 Start Put Dyne (DYN) Back on the Biotech Radar
Positive cardiopulmonary results from the DELIVER trial and the initiation of the Phase 3 HARMONIA study for z-basivarsen (DYNE-101) meaningfully de-risk Dyne's clinical story. With shares trading near $17 and market cap around $2.8B, the setup favors a disciplined long swing trade that captures further validation and potential re-rating as late-st…